GLP-1 medications help regulate appetite, blood sugar, and digestion
At least one serious adverse event occurred among 10.9% of the 36 mg orforglipron group, 10.3% of the 12 mg orforglipron group, 7.3% of those receiving 6 mg orforglipron and 8.8% of the placebo group
Interpretation, therefore, incorporates timing thresholds such as those described in the North American Consensus
Urinary indices, urinary sediment examination, and often imaging and other tests (including sometimes a kidney biopsy) are needed to determine the cause
Some practitioners recommend extended escalation for particularly sensitive individuals, adding an additional 2 to 4 weeks at each dose before advancing
Oral meds at their currently available doses have typically ranged from 5%-7%, though newer studies with higher doses of oral semaglutide are showing results in the 10%-12% range over 68 weeks. So while injections still lead, oral GLP-1 medications are evolving quickly